The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Prophylactic HIV Drug Market Research Report 2025
Synopsis
HIV is one of the leading cause of death worldwide affecting millions of people. HIV has become the chief contributor to the global burden diseases.
The global Prophylactic HIV Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Prophylactic HIV Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prophylactic HIV Drug.
Report Scope
The Prophylactic HIV Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Prophylactic HIV Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Prophylactic HIV Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead Sciences
Merck
Mylan
Cipla
Bristol-Myers Squibb
Roche
Segment by Type
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Integrase Inhibitor
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Prophylactic HIV Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Prophylactic HIV Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
HIV is one of the leading cause of death worldwide affecting millions of people. HIV has become the chief contributor to the global burden diseases.
The global Prophylactic HIV Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Prophylactic HIV Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prophylactic HIV Drug.
Report Scope
The Prophylactic HIV Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Prophylactic HIV Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Prophylactic HIV Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead Sciences
Merck
Mylan
Cipla
Bristol-Myers Squibb
Roche
Segment by Type
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Integrase Inhibitor
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Prophylactic HIV Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Prophylactic HIV Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Prophylactic HIV Drug Market Overview
1.1 Product Overview and Scope of Prophylactic HIV Drug
1.2 Prophylactic HIV Drug Segment by Type
1.2.1 Global Prophylactic HIV Drug Market Value Comparison by Type (2024-2030)
1.2.2 Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
1.2.3 Integrase Inhibitor
1.3 Prophylactic HIV Drug Segment by Application
1.3.1 Global Prophylactic HIV Drug Market Value by Application: (2024-2030)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Global Prophylactic HIV Drug Market Size Estimates and Forecasts
1.4.1 Global Prophylactic HIV Drug Revenue 2019-2030
1.4.2 Global Prophylactic HIV Drug Sales 2019-2030
1.4.3 Global Prophylactic HIV Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Prophylactic HIV Drug Market Competition by Manufacturers
2.1 Global Prophylactic HIV Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Prophylactic HIV Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Prophylactic HIV Drug Average Price by Manufacturers (2019-2024)
2.4 Global Prophylactic HIV Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Prophylactic HIV Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Prophylactic HIV Drug, Product Type & Application
2.7 Prophylactic HIV Drug Market Competitive Situation and Trends
2.7.1 Prophylactic HIV Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Prophylactic HIV Drug Players Market Share by Revenue
2.7.3 Global Prophylactic HIV Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Prophylactic HIV Drug Retrospective Market Scenario by Region
3.1 Global Prophylactic HIV Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Prophylactic HIV Drug Global Prophylactic HIV Drug Sales by Region: 2019-2030
3.2.1 Global Prophylactic HIV Drug Sales by Region: 2019-2024
3.2.2 Global Prophylactic HIV Drug Sales by Region: 2025-2030
3.3 Global Prophylactic HIV Drug Global Prophylactic HIV Drug Revenue by Region: 2019-2030
3.3.1 Global Prophylactic HIV Drug Revenue by Region: 2019-2024
3.3.2 Global Prophylactic HIV Drug Revenue by Region: 2025-2030
3.4 North America Prophylactic HIV Drug Market Facts & Figures by Country
3.4.1 North America Prophylactic HIV Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Prophylactic HIV Drug Sales by Country (2019-2030)
3.4.3 North America Prophylactic HIV Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Prophylactic HIV Drug Market Facts & Figures by Country
3.5.1 Europe Prophylactic HIV Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Prophylactic HIV Drug Sales by Country (2019-2030)
3.5.3 Europe Prophylactic HIV Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Prophylactic HIV Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Prophylactic HIV Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Prophylactic HIV Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Prophylactic HIV Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Prophylactic HIV Drug Market Facts & Figures by Country
3.7.1 Latin America Prophylactic HIV Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Prophylactic HIV Drug Sales by Country (2019-2030)
3.7.3 Latin America Prophylactic HIV Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Prophylactic HIV Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Prophylactic HIV Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Prophylactic HIV Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Prophylactic HIV Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Prophylactic HIV Drug Sales by Type (2019-2030)
4.1.1 Global Prophylactic HIV Drug Sales by Type (2019-2024)
4.1.2 Global Prophylactic HIV Drug Sales by Type (2025-2030)
4.1.3 Global Prophylactic HIV Drug Sales Market Share by Type (2019-2030)
4.2 Global Prophylactic HIV Drug Revenue by Type (2019-2030)
4.2.1 Global Prophylactic HIV Drug Revenue by Type (2019-2024)
4.2.2 Global Prophylactic HIV Drug Revenue by Type (2025-2030)
4.2.3 Global Prophylactic HIV Drug Revenue Market Share by Type (2019-2030)
4.3 Global Prophylactic HIV Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Prophylactic HIV Drug Sales by Application (2019-2030)
5.1.1 Global Prophylactic HIV Drug Sales by Application (2019-2024)
5.1.2 Global Prophylactic HIV Drug Sales by Application (2025-2030)
5.1.3 Global Prophylactic HIV Drug Sales Market Share by Application (2019-2030)
5.2 Global Prophylactic HIV Drug Revenue by Application (2019-2030)
5.2.1 Global Prophylactic HIV Drug Revenue by Application (2019-2024)
5.2.2 Global Prophylactic HIV Drug Revenue by Application (2025-2030)
5.2.3 Global Prophylactic HIV Drug Revenue Market Share by Application (2019-2030)
5.3 Global Prophylactic HIV Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Corporation Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences Prophylactic HIV Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Gilead Sciences Prophylactic HIV Drug Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Prophylactic HIV Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Prophylactic HIV Drug Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Mylan
6.3.1 Mylan Corporation Information
6.3.2 Mylan Description and Business Overview
6.3.3 Mylan Prophylactic HIV Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mylan Prophylactic HIV Drug Product Portfolio
6.3.5 Mylan Recent Developments/Updates
6.4 Cipla
6.4.1 Cipla Corporation Information
6.4.2 Cipla Description and Business Overview
6.4.3 Cipla Prophylactic HIV Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cipla Prophylactic HIV Drug Product Portfolio
6.4.5 Cipla Recent Developments/Updates
6.5 Bristol-Myers Squibb
6.5.1 Bristol-Myers Squibb Corporation Information
6.5.2 Bristol-Myers Squibb Description and Business Overview
6.5.3 Bristol-Myers Squibb Prophylactic HIV Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bristol-Myers Squibb Prophylactic HIV Drug Product Portfolio
6.5.5 Bristol-Myers Squibb Recent Developments/Updates
6.6 Roche
6.6.1 Roche Corporation Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche Prophylactic HIV Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Roche Prophylactic HIV Drug Product Portfolio
6.6.5 Roche Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Prophylactic HIV Drug Industry Chain Analysis
7.2 Prophylactic HIV Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Prophylactic HIV Drug Production Mode & Process
7.4 Prophylactic HIV Drug Sales and Marketing
7.4.1 Prophylactic HIV Drug Sales Channels
7.4.2 Prophylactic HIV Drug Distributors
7.5 Prophylactic HIV Drug Customers
8 Prophylactic HIV Drug Market Dynamics
8.1 Prophylactic HIV Drug Industry Trends
8.2 Prophylactic HIV Drug Market Drivers
8.3 Prophylactic HIV Drug Market Challenges
8.4 Prophylactic HIV Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Prophylactic HIV Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Prophylactic HIV Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Prophylactic HIV Drug Market Competitive Situation by Manufacturers in 2023
Table 4. Global Prophylactic HIV Drug Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Prophylactic HIV Drug Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Prophylactic HIV Drug Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Prophylactic HIV Drug Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Prophylactic HIV Drug Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Prophylactic HIV Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Prophylactic HIV Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Prophylactic HIV Drug, Product Type & Application
Table 12. Global Key Manufacturers of Prophylactic HIV Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Prophylactic HIV Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prophylactic HIV Drug as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Prophylactic HIV Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Prophylactic HIV Drug Sales by Region (2019-2024) & (K Units)
Table 18. Global Prophylactic HIV Drug Sales Market Share by Region (2019-2024)
Table 19. Global Prophylactic HIV Drug Sales by Region (2025-2030) & (K Units)
Table 20. Global Prophylactic HIV Drug Sales Market Share by Region (2025-2030)
Table 21. Global Prophylactic HIV Drug Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Prophylactic HIV Drug Revenue Market Share by Region (2019-2024)
Table 23. Global Prophylactic HIV Drug Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Prophylactic HIV Drug Revenue Market Share by Region (2025-2030)
Table 25. North America Prophylactic HIV Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Prophylactic HIV Drug Sales by Country (2019-2024) & (K Units)
Table 27. North America Prophylactic HIV Drug Sales by Country (2025-2030) & (K Units)
Table 28. North America Prophylactic HIV Drug Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Prophylactic HIV Drug Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Prophylactic HIV Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Prophylactic HIV Drug Sales by Country (2019-2024) & (K Units)
Table 32. Europe Prophylactic HIV Drug Sales by Country (2025-2030) & (K Units)
Table 33. Europe Prophylactic HIV Drug Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Prophylactic HIV Drug Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Prophylactic HIV Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Prophylactic HIV Drug Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Prophylactic HIV Drug Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Prophylactic HIV Drug Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Prophylactic HIV Drug Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Prophylactic HIV Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Prophylactic HIV Drug Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Prophylactic HIV Drug Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Prophylactic HIV Drug Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Prophylactic HIV Drug Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Prophylactic HIV Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Prophylactic HIV Drug Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Prophylactic HIV Drug Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Prophylactic HIV Drug Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Prophylactic HIV Drug Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Prophylactic HIV Drug Sales (K Units) by Type (2019-2024)
Table 51. Global Prophylactic HIV Drug Sales (K Units) by Type (2025-2030)
Table 52. Global Prophylactic HIV Drug Sales Market Share by Type (2019-2024)
Table 53. Global Prophylactic HIV Drug Sales Market Share by Type (2025-2030)
Table 54. Global Prophylactic HIV Drug Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Prophylactic HIV Drug Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Prophylactic HIV Drug Revenue Market Share by Type (2019-2024)
Table 57. Global Prophylactic HIV Drug Revenue Market Share by Type (2025-2030)
Table 58. Global Prophylactic HIV Drug Price (USD/Unit) by Type (2019-2024)
Table 59. Global Prophylactic HIV Drug Price (USD/Unit) by Type (2025-2030)
Table 60. Global Prophylactic HIV Drug Sales (K Units) by Application (2019-2024)
Table 61. Global Prophylactic HIV Drug Sales (K Units) by Application (2025-2030)
Table 62. Global Prophylactic HIV Drug Sales Market Share by Application (2019-2024)
Table 63. Global Prophylactic HIV Drug Sales Market Share by Application (2025-2030)
Table 64. Global Prophylactic HIV Drug Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Prophylactic HIV Drug Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Prophylactic HIV Drug Revenue Market Share by Application (2019-2024)
Table 67. Global Prophylactic HIV Drug Revenue Market Share by Application (2025-2030)
Table 68. Global Prophylactic HIV Drug Price (USD/Unit) by Application (2019-2024)
Table 69. Global Prophylactic HIV Drug Price (USD/Unit) by Application (2025-2030)
Table 70. Gilead Sciences Corporation Information
Table 71. Gilead Sciences Description and Business Overview
Table 72. Gilead Sciences Prophylactic HIV Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Gilead Sciences Prophylactic HIV Drug Product
Table 74. Gilead Sciences Recent Developments/Updates
Table 75. Merck Corporation Information
Table 76. Merck Description and Business Overview
Table 77. Merck Prophylactic HIV Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Merck Prophylactic HIV Drug Product
Table 79. Merck Recent Developments/Updates
Table 80. Mylan Corporation Information
Table 81. Mylan Description and Business Overview
Table 82. Mylan Prophylactic HIV Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Mylan Prophylactic HIV Drug Product
Table 84. Mylan Recent Developments/Updates
Table 85. Cipla Corporation Information
Table 86. Cipla Description and Business Overview
Table 87. Cipla Prophylactic HIV Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Cipla Prophylactic HIV Drug Product
Table 89. Cipla Recent Developments/Updates
Table 90. Bristol-Myers Squibb Corporation Information
Table 91. Bristol-Myers Squibb Description and Business Overview
Table 92. Bristol-Myers Squibb Prophylactic HIV Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Bristol-Myers Squibb Prophylactic HIV Drug Product
Table 94. Bristol-Myers Squibb Recent Developments/Updates
Table 95. Roche Corporation Information
Table 96. Roche Description and Business Overview
Table 97. Roche Prophylactic HIV Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Roche Prophylactic HIV Drug Product
Table 99. Roche Recent Developments/Updates
Table 100. Key Raw Materials Lists
Table 101. Raw Materials Key Suppliers Lists
Table 102. Prophylactic HIV Drug Distributors List
Table 103. Prophylactic HIV Drug Customers List
Table 104. Prophylactic HIV Drug Market Trends
Table 105. Prophylactic HIV Drug Market Drivers
Table 106. Prophylactic HIV Drug Market Challenges
Table 107. Prophylactic HIV Drug Market Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Prophylactic HIV Drug
Figure 2. Global Prophylactic HIV Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Prophylactic HIV Drug Market Share by Type in 2023 & 2030
Figure 4. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Product Picture
Figure 5. Integrase Inhibitor Product Picture
Figure 6. Global Prophylactic HIV Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Prophylactic HIV Drug Market Share by Application in 2023 & 2030
Figure 8. Hospital Pharmacy
Figure 9. Retail Pharmacy
Figure 10. Online Pharmacy
Figure 11. Global Prophylactic HIV Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Prophylactic HIV Drug Market Size (2019-2030) & (US$ Million)
Figure 13. Global Prophylactic HIV Drug Sales (2019-2030) & (K Units)
Figure 14. Global Prophylactic HIV Drug Average Price (USD/Unit) & (2019-2030)
Figure 15. Prophylactic HIV Drug Report Years Considered
Figure 16. Prophylactic HIV Drug Sales Share by Manufacturers in 2023
Figure 17. Global Prophylactic HIV Drug Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Prophylactic HIV Drug Players: Market Share by Revenue in 2023
Figure 19. Prophylactic HIV Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Prophylactic HIV Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Prophylactic HIV Drug Sales Market Share by Country (2019-2030)
Figure 22. North America Prophylactic HIV Drug Revenue Market Share by Country (2019-2030)
Figure 23. U.S. Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Prophylactic HIV Drug Sales Market Share by Country (2019-2030)
Figure 26. Europe Prophylactic HIV Drug Revenue Market Share by Country (2019-2030)
Figure 27. Germany Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Prophylactic HIV Drug Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Prophylactic HIV Drug Revenue Market Share by Region (2019-2030)
Figure 34. China Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Taiwan Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Philippines Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Prophylactic HIV Drug Sales Market Share by Country (2019-2030)
Figure 45. Latin America Prophylactic HIV Drug Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Prophylactic HIV Drug Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Prophylactic HIV Drug Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. U.A.E Prophylactic HIV Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Prophylactic HIV Drug by Type (2019-2030)
Figure 55. Global Revenue Market Share of Prophylactic HIV Drug by Type (2019-2030)
Figure 56. Global Prophylactic HIV Drug Price (USD/Unit) by Type (2019-2030)
Figure 57. Global Sales Market Share of Prophylactic HIV Drug by Application (2019-2030)
Figure 58. Global Revenue Market Share of Prophylactic HIV Drug by Application (2019-2030)
Figure 59. Global Prophylactic HIV Drug Price (USD/Unit) by Application (2019-2030)
Figure 60. Prophylactic HIV Drug Value Chain
Figure 61. Prophylactic HIV Drug Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
